Mediators of Inflammation / 2020 / Article / Tab 1

Research Article

Increased Serum Interleukin-2 Levels Are Associated with Abnormal Peripheral Blood Natural Killer Cell Levels in Patients with Active Rheumatoid Arthritis

Table 1

Clinical characteristics of RA patients in each disease activity group.
(a)

Remission group (A) (n = 33)Low disease activity group (B) (n = 38)Moderate-high disease activity group (C) (n = 35)p A vs. Bp A vs. Cp B vs. C

Demographics
Age (years)a45.09 ± 13.7747.18 ± 16.4149.20 ± 14.600.4740.3020.778
Male, n (%)11 (33.33%)4 (10.53%)10 (28.57%)
Female, n (%)22 (66.67%)34(89.47%)25 (71.43%)
Course of disease (month)b10.00 6.25-12.759.00 5.75-15.2512.00 7.00-17.000.9570.2730.342
Height (m)a1.63 ± 0.071.61 ± 0.0631.63 ± 0.0720.6320.8610.502
Weight (kg)a64.39 ± 16.9658.95 ± 9.9259.69 ± 10.150.2860.7400.635
BMIa24.10 ± 4.6022.66 ± 3.2222.34 ± 3.160.2560.1750.781
ESR, (mm/h)b10.50 6.00-15.7520.00 10.00-34.2543.00 33.00-63.000.003< 0.001< 0.001
CRP (mg/ml)b4.10 2.56-7.417.273.66-16.3010.104.88-22.480.2210.0080.134
VAS scoreb10.00 5.00-15.0015.00 11.25-25.0035.00 25.00-50.000.002< 0.0010.001
DAS28 score a1.87 ± 0.602.78 ± 0.394.84 ± 0.67< 0.001< 0.001< 0.001
b6.80 5.30-8.776.80 5.45-9.057.40 5.00-9.100.7821.0000.710
Hb (g/l)a137.95 ± 16.77124.75 ± 13.56123.11 ± 16.360.001< 0.0010.527
229.00 187.50-277.40237.50 204.00-308.60251.00 179.00-315.000.3400.4040.968
2.10 1.60-2.471.79 1.31-2.501.68 1.05-2.190.0580.0090.446
RF (U/ml)b82.35 40.00-184.7580.00 40.00-294.8080.00 40.00-160.000.4840.8350.362
Anti-CCP (RU/ml)b397.45 39.98-1476.66598.85 130.76-1300.03394.80 187.90-1000.000.6590.5690.771

(b)

Remission group (A) ()Low disease activity group (B) ()Moderate-high disease activity group (C) (), A vs. B, A vs. C, B vs. C

Medication type
NSAIDS, (%)11 (33.33%)27 (71.05%)22 (62.86%)
CS, (%)12 (36.36%)26 (68.42%)25 (71.43%)
Oral prednisone dose (mg/day)b7.50
4.38-10.00
10.00
5.00-12.50
10.00
8.75-13.75
0.1390.0150.311
Prednisone use time (month)b3.65
2.80-4.00
4.00
2.75-5.25
4.00
2.25-5.00
0.0760.5460.301
MTX, (%)3 (9.09%)5 (13.16%)5 (14.29%)
LEF, (%)3 (9.09%)3 (7.89%)4 (11.43%)
HCQ, (%)5 (15.16%)7 (18.42%)5 (14.29%)
TNF-ɑ inhibitors, (%) (50 mg/week)5 (15.16%)9 (23.68%)12 (34.29%)
TNF-ɑ inhibitor use time (week)b5.50
2.50-7.75
6.00
3.00-11.00
7.00
3.00-9.00
0.6240.4890.691

aResults are expressed as the . bResults are expressed as the median and 25th and 75th percentiles. The independent-samples -test was used for analysis of quantitative variables with normal distributions. Wilcoxon’s rank sum test was used for analysis of quantitative variables with a nonnormal distribution. Abbreviations: RA: rheumatoid arthritis; BMI: body mass index; ESR: erythrocyte sedimentation rate; CRP: C-reaction protein; VAS: visual analogue scale; WBC: white blood cells; Hb: hemoglobin; PLT: platelets; LY: lymphocytes; RF: rheumatoid factor; Anti-CCP: anticyclic citrullinated peptide antibodies; MTX: methotrexate; LEF: leflunomide; HCQ: hydroxychloroquine; CS: corticosteroid; NSAID: nonsteroidal anti-inflammatory drug.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.